Immediate breast reconstruction in locally advanced breast cancer: is it safe?

Abstract

Immediate breast reconstruction (IBR) following mastectomy remains controversial for locally advanced breast cancer over concerns regarding recurrence and complications which may delay adjuvant therapies. This study aimed to compare the oncologic outcomes and surgical safety of IBR following mastectomy with mastectomy alone (MA) for locally advanced breast cancer. All patients treated at the Providence Breast Center between 2012 and 2017 for biopsy-proven locally advanced breast cancer, AJCC (8th edition) clinical stages (IIB–IIIC), were included. Primary outcomes were overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS). Secondary outcomes included recurrence rate, adjuvant therapy use, and reoperation. 267 patients (112 IBR, 155 MA) were included. On average, IBR patients were younger (48.82 years vs 61.42 years, P\u2009<\u20090.001). Median study follow-up was 50.7 months. OS was higher among IBR patients (86.6% vs 73.5%, P\u2009<\u20090.05). However, no significant differences were found in DSS (87.5% vs 84.5%, P\u2009=\u20090.34), DFS (79.5% vs 78.7%, P\u2009=\u20090.55), local recurrence (0% vs 1.9%, P\u2009=\u20090.194), adjuvant therapy use (95.5% vs 91.6%, P\u2009=\u20090.155), or reoperation (1.8% vs 1.3%, P\u2009=\u20090.559). IBR is a safe option for patients with locally advanced breast cancer and does not negatively impact survival, cancer recurrence rates, and use of adjuvant therapy.